| Drug Name |
Fludrocortisone |
| Drug ID |
BADD_D00917 |
| Description |
Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency.[A5423] |
| Indications and Usage |
Fludrocortisone is indicated as partial replacement therapy for primary or secondary adrenocortical insufficiency in Addison's disease. It is also indicated for the treatment of salt-losing androgenital syndrome.[L8971] |
| Marketing Status |
approved; investigational |
| ATC Code |
H02AA02 |
| DrugBank ID |
DB00687
|
| KEGG ID |
D07967
|
| MeSH ID |
D005438
|
| PubChem ID |
31378
|
| TTD Drug ID |
D0R7JT
|
| NDC Product Code |
Not Available |
| UNII |
U0476M545B
|
| Synonyms |
Fludrocortisone | 9-Fluorocortisol | 9 Fluorocortisol | 9 alpha Fludrohydrocortisone | 9 alpha-Fluoro-17-Hydroxycorticosterone | 9 alpha Fluoro 17 Hydroxycorticosterone | 9-Fluoro-17-Hydroxycortisone | 9 Fluoro 17 Hydroxycortisone | 9-Fluorohydrocortisone | 9 Fluorohydrocortisone | 9 alpha-Fluorohydrocortisone | 9 alpha Fluorohydrocortisone | Astonin | Astonin-H | Astonin H | Astonin Merck | Merck, Astonin | FCOL |
